Multifunctional Flexible AgNW/MXene/PDMS Composite Films for Efficient Electromagnetic Interference Shielding and Strain Sensing.

With the rapid development of electronic information technology, composite materials with outstanding performance in terms of electromagnetic interference (EMI) shielding and strain sensing are crucial for next-generation smart wearable electronic devices. However, the fabrication of flexible composite films with dual functionality remains a significant challenge. Herein, multifunctional flexible composite films with exciting EMI shielding and strain sensing properties were constructed using a facile vacuum-assisted filtration process and transfer method. The films consisted of ultrathin AgNW/MXene (Ti3C2Tx)/AgNW conductive networks (1 µm) attached to a flexible polydimethylsiloxane (PDMS) substrate. The obtained AgNW/MXene/PDMS composite film exhibited an exceptional EMI shielding effectiveness of 50.82 dB and good flexibility (retaining 93.67 and 90.18% of its original value after 1000 bending and stretching cycles, respectively), which are attributed to the enhanced multilayer internal reflection network created by the AgNWs and MXene as well as the synergistic effect of PDMS. Besides EMI shielding, the composite films also displayed remarkable strain sensing properties. They exhibited a wide linear range of tensile strain up to 68% with a gauge factor of 468. They also showed fast response, ultralow detection limit, and high mechanical stability. Interestingly, the composite films could also detect motion and voice recognition, demonstrating their potential as wearable sensors. This study highlights the effectiveness of multifunctional flexible AgNW/MXene/PDMS composite films in resisting electromagnetic radiation and monitoring human motion, thereby providing a promising solution for the development of flexible wearable electronic devices in complex electromagnetic environments.

Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms.

Glioma is the most common primary craniocerebral malignant tumor, arising from the canceration of glial cells in the brain and spinal cord. The quality of life and prognosis of patients with this disease are still poor. Doxorubicin (DOX) is one of the most traditional and economical chemotherapeutic drugs for the treatment of glioma, but its toxic effect on normal cells and the resistance of tumor cells to DOX make the application of DOX in the treatment of glioma gradually less effective. To solve this problem, we co-encapsulated DOX and endogenous tumor suppressor miR-125b into nanoparticles (NPs) by nanoprecipitation methods, and passively targeted them into glioma cells. In vitro experiments show that miR-125b and DOX can be effectively encapsulated into nanoparticles with different ratios, and by targeting YES proto-oncogene 1 (YES1), they can affect the adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/p53 pathway and induce brain glioma cell apoptosis. They can also affect the DNA damage repair process and inhibit cell proliferation. The obtained data suggest that co-delivery of DOX and miR-125b could achieve synergistic effects on tumor suppression. Nanosystem-based co-delivery of tumor suppressive miRNAs and chemotherapeutic agents may be a promising combined therapeutic strategy for enhanced anti-tumor therapy.

Targeting the mTOR pathway in breast cancer.

Mechanistic target of rapamycin controls cell growth, metabolism, and aging in response to nutrients, cellular energy stage, and growth factors. In cancers including breast cancer, mechanistic target of rapamycin is frequently upregulated. Blocking mechanistic target of rapamycin with rapamycin, first-generation and second-generation mechanistic target of rapamycin inhibitors, called rapalogs, have shown potent reduction of breast cancer tumor growth in preclinical models and clinical trials. In this review, we summarize the fundamental role of the mechanistic target of rapamycin pathway in driving breast tumors. Moreover, we also review key molecules involved with aberrant mechanistic target of rapamycin pathway activation in breast cancer and current efforts to target these components for therapeutic gain. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the mechanistic target of rapamycin pathway.